Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.260
+0.030 (2.44%)
At close: Feb 21, 2025
Duopharma Biotech Berhad Cash Flow Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 62.65 | 52.65 | 70.11 | 65.68 | 58.61 | Upgrade
|
| Depreciation & Amortization | 45.43 | 38.76 | 33.48 | 29.66 | 27.56 | Upgrade
|
| Other Amortization | - | 4.29 | 2.72 | 2.29 | 1.51 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.4 | - | - | 0.01 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 2.43 | - | 0.1 | 1.1 | Upgrade
|
| Provision & Write-off of Bad Debts | -1.51 | 4.1 | -0.49 | 0.1 | -0.82 | Upgrade
|
| Other Operating Activities | 10.29 | -7.11 | 22.74 | 7.29 | 12.69 | Upgrade
|
| Change in Accounts Receivable | -47.08 | -5.81 | -13.28 | -4.14 | 4.54 | Upgrade
|
| Change in Inventory | -15.35 | -12.39 | -53.36 | -78.43 | -21.37 | Upgrade
|
| Change in Accounts Payable | 28.13 | -28.1 | 8.35 | 20.64 | -12.48 | Upgrade
|
| Operating Cash Flow | 82.16 | 48.8 | 70.27 | 43.2 | 71.35 | Upgrade
|
| Operating Cash Flow Growth | 68.36% | -30.54% | 62.64% | -39.45% | 6.56% | Upgrade
|
| Capital Expenditures | -22.33 | -32.95 | -65.18 | -109.36 | -56.11 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.5 | - | - | 0.02 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -10.41 | -6.61 | -5.84 | -5.64 | -9.51 | Upgrade
|
| Investment in Securities | - | -6.42 | - | -2.07 | 2.68 | Upgrade
|
| Other Investing Activities | 5.97 | 2.75 | 1.52 | 1.2 | 1.51 | Upgrade
|
| Investing Cash Flow | -26.27 | -43.23 | -69.5 | -115.86 | -61.43 | Upgrade
|
| Long-Term Debt Issued | 93.15 | 486.35 | 85.67 | 186.78 | 193.81 | Upgrade
|
| Long-Term Debt Repaid | -128.63 | -369.97 | -59.27 | -89.46 | -158.74 | Upgrade
|
| Net Debt Issued (Repaid) | -35.48 | 116.37 | 26.4 | 97.33 | 35.07 | Upgrade
|
| Common Dividends Paid | -26.93 | -8.85 | -8.2 | -44.96 | -7.23 | Upgrade
|
| Financing Cash Flow | -62.42 | 107.52 | 18.2 | 52.37 | 27.83 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.56 | -0.23 | 0.69 | 0.24 | -0.4 | Upgrade
|
| Net Cash Flow | -5.96 | 112.87 | 19.66 | -20.05 | 37.36 | Upgrade
|
| Free Cash Flow | 59.84 | 15.86 | 5.08 | -66.16 | 15.24 | Upgrade
|
| Free Cash Flow Growth | 277.34% | 211.98% | - | - | 12.09% | Upgrade
|
| Free Cash Flow Margin | 7.35% | 2.25% | 0.73% | -10.35% | 2.67% | Upgrade
|
| Free Cash Flow Per Share | 0.06 | 0.02 | 0.01 | -0.07 | 0.02 | Upgrade
|
| Cash Interest Paid | 27.04 | 21.71 | 16.54 | 11.97 | 6.34 | Upgrade
|
| Cash Income Tax Paid | 10.75 | 16.83 | 24.51 | 11.66 | 18.12 | Upgrade
|
| Levered Free Cash Flow | 32.22 | -10.33 | -6.71 | -60.93 | -7.67 | Upgrade
|
| Unlevered Free Cash Flow | 48.84 | 0.72 | -1.02 | -56.91 | -3.59 | Upgrade
|
| Change in Net Working Capital | 26.77 | 51.97 | 24.27 | 29.34 | 18.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.